27,770 Shares in Exelixis, Inc. (NASDAQ:EXEL) Purchased by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. bought a new stake in Exelixis, Inc. (NASDAQ:EXEL) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 27,770 shares of the biotechnology company’s stock, valued at approximately $721,000.

Several other hedge funds also recently modified their holdings of EXEL. V Square Quantitative Management LLC purchased a new position in shares of Exelixis during the third quarter valued at approximately $30,000. Park Place Capital Corp acquired a new position in Exelixis in the 2nd quarter valued at $45,000. GAMMA Investing LLC lifted its stake in shares of Exelixis by 107.9% during the 2nd quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 1,041 shares during the period. EntryPoint Capital LLC boosted its holdings in shares of Exelixis by 537.2% during the first quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 1,746 shares during the last quarter. Finally, Capital Performance Advisors LLP purchased a new stake in shares of Exelixis in the third quarter valued at $61,000. 85.27% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

EXEL has been the topic of several recent analyst reports. Piper Sandler increased their target price on Exelixis from $33.00 to $36.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. Stephens raised their target price on shares of Exelixis from $23.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $34.00 price target on shares of Exelixis in a research report on Wednesday, October 30th. UBS Group assumed coverage on shares of Exelixis in a report on Thursday, September 19th. They issued a “neutral” rating and a $30.00 price target on the stock. Finally, Bank of America boosted their price objective on shares of Exelixis from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, October 15th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $31.44.

Insider Transactions at Exelixis

In other Exelixis news, EVP Jeffrey Hessekiel sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $25.79, for a total transaction of $515,800.00. Following the completion of the sale, the executive vice president now owns 630,325 shares in the company, valued at $16,256,081.75. This trade represents a 3.08 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Patrick J. Haley sold 41,588 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $34.36, for a total value of $1,428,963.68. Following the completion of the transaction, the executive vice president now directly owns 288,665 shares in the company, valued at approximately $9,918,529.40. The trade was a 12.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 289,736 shares of company stock valued at $9,471,510. 2.85% of the stock is currently owned by insiders.

Exelixis Stock Up 2.2 %

NASDAQ EXEL opened at $35.61 on Friday. Exelixis, Inc. has a fifty-two week low of $19.20 and a fifty-two week high of $36.60. The business has a 50 day moving average price of $29.90 and a two-hundred day moving average price of $25.60. The stock has a market cap of $10.17 billion, a PE ratio of 22.83, a P/E/G ratio of 0.88 and a beta of 0.51.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.36 by $0.04. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The business had revenue of $539.50 million during the quarter, compared to the consensus estimate of $490.31 million. During the same period in the prior year, the firm earned $0.10 earnings per share. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. Sell-side analysts anticipate that Exelixis, Inc. will post 1.69 EPS for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.